Swedish comment: Leqembi recommended for early Alzheimer's disease in Europe

The first drug to slow Alzheimer's disease has now been recommended for use in Europe. The drug has been shown to reduce disease progression by about 30 percent in the early stages of the disease. In a report on TV4, researchers and a study participant share their experiences of being part of the study. We encourage those who want to learn more to watch the TV4 clip (Swedish): TV4-clip.

For more information and context regarding the recommendation of the drug (Leqembi) for treatment, we refer to the article we have published below, where we discuss the decision from the European Medicines Agency.